drugset
drugset / Trial / NCT04944953

To Compare the Safety and Efficacy of "HG-102" With Botox® in the Improvement of Moderate to Severe Glabellar Lines.

NCT04944953 ↗

Phase 1 Completed 38 enrolled Hugel
RandomizedParallel-groupDouble-blindTreatment

Summary

To compare the safety and efficacy of "HG-102" with Botox® in the improvement of moderate to severe glabellar lines.

Timeline

Start
2021-06-11
Primary completion
2021-09-02
Completion
2021-12-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic 20 iu —

Indications

No indication recorded.